This study emphasises the development of PROTACs that selectively and effectively target SMARCA2 in vivo through the conversion of non‐selective SMARCA2/4‐binding ligands, thereby potentially offering a new therapeutic opportunity for patients with tumours harbouring SMARCA4 mutations [68]. Here, SMARCA4 is linked to neoplasm.